Therapeutic indications of hemopoietic growth factors in hematologic diseases (Meeting abstract).

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Therapeutic indications of hemopoietic growth factors in hematologic diseases (Meeting abstract).

Eighth Mediterranean Congress of Chemotherapy. May 24-29, 1992, Athens, Greece, p. 625, 1992.. Unique Identifier : AIDSLINE ICDB/93688738
Kallinikos-Maniatis A; Lab. of Hematology and Transfusion Medicine, Univ. of Patras,; Greece

Abstract: Hemopoietic growth factors have recently been incorporated in a number of clinical trials both in hematology and in oncology, and results (although preliminary) are certainly promising. Correction of anemia by the administration of rEPO has been achieved in anemia of renal failure and responses have been observed in a number of other anemias (such as that of AIDS, rheumatoid arthritis, myeloma, cancer and pure red cell aplasia). G-CSF has shown significant activity in raising the circulating neutrophil counts in myelodysplastic syndromes (MDS), congenital neutropenic states, idiopathic neutropenia, cyclic neutropenia and neutropenia associated with hairy-cell leukemia. GM-CSF, a cytokine that stimulates the growth of granulocytes and macrophages, is under intensive study in a large number of clinical trials. Emphasis is placed on treatment of MDS, in combination with rEPO, to accelerate hematopoietic recovery following chemotherapy (CT) and enhance peripheral blood stem cell (PBSC) collection for autologous reconstitution. In addition, it is being incorporated in the treatment of AML either immediately after CT, to decrease the duration of neutropenia, or (more importantly) before CT, in an attempt to increase neoplastic cell kill. Responses with GM-CSF have also been observed in severe aplastic anemia and Fanconi's anemia. IL-3 or multi-CSF is also under study alone or in combination with other cytokines for the treatment of MDS and the Diamond Blackfan Syndrome, for CT-induced neutropenias and for PBSC collection. Finally, the recently identified stem cell factor (c-kit ligand) has not yet entered clinical studies, but animal studies show great promise.

Keywords: Acquired Immunodeficiency Syndrome/THERAPY Anemia/THERAPY Arthritis, Rheumatoid/THERAPY Erythropoietin/*THERAPEUTIC USE Granulocyte Colony-Stimulating Factor/*THERAPEUTIC USE Granulocyte-Macrophage Colony-Stimulating Factor/*THERAPEUTIC USE Hematopoietic Cell Growth Factors/METABOLISM Hematopoietic Stem Cells/CYTOLOGY Human Leukemia, Hairy Cell/THERAPY Multiple Myeloma/THERAPY Myelodysplastic Syndromes/*THERAPY Neutropenia/CHEMICALLY INDUCED/THERAPY Red-Cell Aplasia, Pure/THERAPY ABSTRACT
930430
M9340821

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .